

# Richard P Allen

## List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/59088/publications.pdf>

Version: 2024-02-01

213  
papers

24,565  
citations

7096

78  
h-index

7160

153  
g-index

215  
all docs

215  
docs citations

215  
times ranked

7068  
citing authors

#	ARTICLE	IF	CITATIONS
1	Restless legs syndrome: diagnostic criteria, special considerations, and epidemiology. <i>Sleep Medicine</i> , 2003, 4, 101-119.	1.6	2,868
2	Validation of the International Restless Legs Syndrome Study Group rating scale for restless legs syndrome. <i>Sleep Medicine</i> , 2003, 4, 121-132.	1.6	1,488
3	Restless legs syndrome/Willis-Ekbom disease diagnostic criteria: updated International Restless Legs Syndrome Study Group (IRLSSG) consensus criteria – history, rationale, description, and significance. <i>Sleep Medicine</i> , 2014, 15, 860-873.	1.6	1,123
4	Restless Legs Syndrome Prevalence and Impact. <i>Archives of Internal Medicine</i> , 2005, 165, 1286.	3.8	1,046
5	Toward a better definition of the restless legs syndrome. <i>Movement Disorders</i> , 1995, 10, 634-642.	3.9	1,004
6	Impact, diagnosis and treatment of restless legs syndrome (RLS) in a primary care population: the REST (RLS epidemiology, symptoms, and treatment) primary care study. <i>Sleep Medicine</i> , 2004, 5, 237-246.	1.6	588
7	Restless Legs Syndrome. <i>Journal of Clinical Neurophysiology</i> , 2001, 18, 128-147.	1.7	474
8	The official World Association of Sleep Medicine (WASM) standards for recording and scoring periodic leg movements in sleep (PLMS) and wakefulness (PLMW) developed in collaboration with a task force from the International Restless Legs Syndrome Study Group (IRLSSG). <i>Sleep Medicine</i> , 2006, 7, 175-183.	1.6	444
9	Augmentation of the Restless Legs Syndrome With Carbidopa/Levodopa. <i>Sleep</i> , 1996, 19, 205-213.	1.1	424
10	Restless Legs Syndrome: Prevalence and Impact in Children and Adolescents – The Peds REST Study. <i>Pediatrics</i> , 2007, 120, 253-266.	2.1	377
11	Dopamine and iron in the pathophysiology of restless legs syndrome (RLS). <i>Sleep Medicine</i> , 2004, 5, 385-391.	1.6	366
12	Iron and The Restless Legs Syndrome. <i>Sleep</i> , 1998, 21, 381-387.	1.1	324
13	Altered dopaminergic profile in the putamen and substantia nigra in restless leg syndrome. <i>Brain</i> , 2009, 132, 2403-2412.	7.6	299
14	An Algorithm for the Management of Restless Legs Syndrome. <i>Mayo Clinic Proceedings</i> , 2004, 79, 916-922.	3.0	287
15	An Update on the Dopaminergic Treatment of Restless Legs Syndrome and Periodic Limb Movement Disorder. <i>Sleep</i> , 2004, 27, 560-583.	1.1	283
16	Restless legs syndrome associated with major diseases. <i>Neurology</i> , 2016, 86, 1336-1343.	1.1	276
17	Diagnostic Standards for Dopaminergic Augmentation of Restless Legs Syndrome: Report from a World Association of Sleep Medicine – International Restless Legs Syndrome Study Group Consensus Conference at the Max Planck Institute. <i>Sleep Medicine</i> , 2007, 8, 520-530.	1.6	264
18	Evaluating the quality of life of patients with restless legs syndrome. <i>Clinical Therapeutics</i> , 2004, 26, 925-935.	2.5	263

#	ARTICLE	IF	CITATIONS
19	The long-term treatment of restless legs syndrome/Willis-Ekbom disease: evidence-based guidelines and clinical consensus best practice guidance: a report from the International Restless Legs Syndrome Study Group. <i>Sleep Medicine</i> , 2013, 14, 675-684.	1.6	260
20	Altered Brain iron homeostasis and dopaminergic function in Restless Legs Syndrome (Willis-Ekbom) Tj ETQq0 0,0,rgBT /Oyerklock 10 251	1.6	251
21	The four diagnostic criteria for Restless Legs Syndrome are unable to exclude confounding conditions (â€œmimicsâ€œ). <i>Sleep Medicine</i> , 2009, 10, 976-981.	1.6	246
22	The role of iron in restless legs syndrome. <i>Movement Disorders</i> , 2007, 22, S440-S448.	3.9	243
23	Treatment of restless legs syndrome: An evidence-based review and implications for clinical practice. <i>Movement Disorders</i> , 2008, 23, 2267-2302.	3.9	242
24	Guidelines for the first-line treatment of restless legs syndrome/Willis-Ekbom disease, prevention and treatment of dopaminergic augmentation: a combined task force of the IRLSSG, EURLSSG, and the RLS-foundation. <i>Sleep Medicine</i> , 2016, 21, 1-11.	1.6	242
25	Evidence-based and consensus clinical practice guidelines for the iron treatment of restless legs syndrome/Willis-Ekbom disease in adults and children: an IRLSSG task force report. <i>Sleep Medicine</i> , 2018, 41, 27-44.	1.6	228
26	Ropinirole Decreases Periodic Leg Movements and Improves Sleep Parameters in Patients with Restless Legs Syndrome. <i>Sleep</i> , 2004, 27, 907-914.	1.1	225
27	MRI-determined regional brain iron concentrations in early- and late-onset restless legs syndrome. <i>Sleep Medicine</i> , 2006, 7, 458-461.	1.6	219
28	Defining the phenotype of the restless legs syndrome (RLS) using age-of-symptom-onset. <i>Sleep Medicine</i> , 2000, 1, 11-19.	1.6	211
29	Insight into the pathophysiology of restless legs syndrome. <i>Journal of Neuroscience Research</i> , 2000, 62, 623-628.	2.9	209
30	Profile of altered brain iron acquisition in restless legs syndrome. <i>Brain</i> , 2011, 134, 959-968.	7.6	203
31	Restless Legs Syndrome Symptoms in Primary Care. <i>Archives of Internal Medicine</i> , 2003, 163, 2323.	3.8	192
32	Identification of novel risk loci for restless legs syndrome in genome-wide association studies in individuals of European ancestry: a meta-analysis. <i>Lancet Neurology</i> , The, 2017, 16, 898-907.	10.2	191
33	The treatment of restless legs syndrome with intravenous iron dextran. <i>Sleep Medicine</i> , 2004, 5, 231-235.	1.6	190
34	The prevalence and impact of restless legs syndrome on patients with iron deficiency anemia. <i>American Journal of Hematology</i> , 2013, 88, 261-264.	4.1	189
35	Comparison of Pregabalin with Pramipexole for Restless Legs Syndrome. <i>New England Journal of Medicine</i> , 2014, 370, 621-631.	27.0	189
36	Prolonged release oxycodone-naloxone for treatment of severe restless legs syndrome after failure of previous treatment: a double-blind, randomised, placebo-controlled trial with an open-label extension. <i>Lancet Neurology</i> , The, 2013, 12, 1141-1150.	10.2	188

#	ARTICLE	IF	CITATIONS
37	Prevalence and disease burden of primary restless legs syndrome: Results of a general population survey in the United States. <i>Movement Disorders</i> , 2011, 26, 114-120.	3.9	187
38	Pergolide and Carbidopa/Levodopa Treatment of the Restless Legs Syndrome and Periodic Leg Movements in Sleep in a Consecutive Series of Patients. <i>Sleep</i> , 1996, 19, 801-810.	1.1	184
39	Practice guideline summary: Treatment of restless legs syndrome in adults. <i>Neurology</i> , 2016, 87, 2585-2593.	1.1	182
40	Validation of the self-completed Cambridge-Hopkins questionnaire (CH-RLSq) for ascertainment of restless legs syndrome (RLS) in a population survey. <i>Sleep Medicine</i> , 2009, 10, 1097-1100.	1.6	181
41	Physician-diagnosed restless legs syndrome in a large sample of primary medical care patients in western Europe: Prevalence and characteristics. <i>Sleep Medicine</i> , 2010, 11, 31-37.	1.6	177
42	Comorbidities, treatment, and pathophysiology in restless legs syndrome. <i>Lancet Neurology</i> , The, 2018, 17, 994-1005.	10.2	166
43	Genome-Wide Association Study Identifies Novel Restless Legs Syndrome Susceptibility Loci on 2p14 and 16q12.1. <i>PLoS Genetics</i> , 2011, 7, e1002171.	3.5	163
44	Validation of the Johns Hopkins restless legs severity scale. <i>Sleep Medicine</i> , 2001, 2, 239-242.	1.6	162
45	A 10-year, longitudinal assessment of dopamine agonists and methadone in the treatment of restless legs syndrome. <i>Sleep Medicine</i> , 2011, 12, 440-444.	1.6	159
46	Thalamic glutamate/glutamine in restless legs syndrome. <i>Neurology</i> , 2013, 80, 2028-2034.	1.1	156
47	Restless Legs Syndrome is Associated with DSM-IV Major Depressive Disorder and Panic Disorder in the Community. <i>Journal of Neuropsychiatry and Clinical Neurosciences</i> , 2008, 20, 101-105.	1.8	154
48	Treatment of restless legs syndrome: Evidence-based review and implications for clinical practice (Revised 2017). <i>Movement Disorders</i> , 2018, 33, 1077-1091.	3.9	136
49	Clinical efficacy and safety of IV ferric carboxymaltose (FCM) treatment of RLS: A multi-centred, placebo-controlled preliminary clinical trial. <i>Sleep Medicine</i> , 2011, 12, 906-913.	1.6	126
50	The Dopamine Transporter is Decreased in the Striatum of Subjects with Restless Legs Syndrome. <i>Sleep</i> , 2011, 34, 341-347.	1.1	126
51	Restless Leg Syndrome/Willis-Ekbom Disease Pathophysiology. <i>Sleep Medicine Clinics</i> , 2015, 10, 207-214.	2.6	126
52	Restless legs syndrome (RLS) augmentation associated with dopamine agonist and levodopa usage in a community sample. <i>Sleep Medicine</i> , 2011, 12, 431-439.	1.6	123
53	Epidemiology of Restless Legs Syndrome in Korean Adults. <i>Sleep</i> , 2008, 31, 219-223.	1.1	119
54	When gender matters: Restless legs syndrome. Report of the RLS and woman workshop endorsed by the European RLS Study Group. <i>Sleep Medicine Reviews</i> , 2012, 16, 297-307.	8.5	115

#	ARTICLE	IF	CITATIONS
55	A randomized, double-blind, placebo-controlled trial of intravenous iron sucrose in restless legs syndrome. <i>Sleep Medicine</i> , 2009, 10, 206-211.	1.6	114
56	Factor analysis of the International Restless Legs Syndrome Study Group's scale for restless legs severity. <i>Sleep Medicine</i> , 2003, 4, 133-135.	1.6	112
57	Controversies and Challenges in Defining the Etiology and Pathophysiology of Restless Legs Syndrome. <i>American Journal of Medicine</i> , 2007, 120, S13-S21.	1.5	112
58	Persistent Effects of (±)3,4-Methylenedioxymethamphetamine (MDMA, "Ecstasy") on Human Sleep. <i>Sleep</i> , 1993, 16, 560-564.	1.1	108
59	Validation of the Restless Legs Syndrome Quality of Life Questionnaire. <i>Value in Health</i> , 2005, 8, 157-167.	0.3	105
60	Ferritin Levels in the Cerebrospinal Fluid and Restless Legs Syndrome: Effects of Different Clinical Phenotypes. <i>Sleep</i> , 2005, 28, 1069-1075.	1.1	104
61	Rotigotine improves restless legs syndrome: A 6-month randomized, double-blind, placebo-controlled trial in the United States. <i>Movement Disorders</i> , 2010, 25, 1675-1683.	3.9	102
62	Repeated IV doses of iron provides effective supplemental treatment of restless legs syndrome. <i>Sleep Medicine</i> , 2005, 6, 301-305.	1.6	101
63	Validation of the Hopkins telephone diagnostic interview for restless legs syndrome. <i>Sleep Medicine</i> , 2008, 9, 283-289.	1.6	100
64	Validation of the Augmentation Severity Rating Scale (ASRS): A multicentric, prospective study with levodopa on restless legs syndrome. <i>Sleep Medicine</i> , 2007, 8, 455-463.	1.6	97
65	Psychometric evaluation and tests of validity of the Medical Outcomes Study 12-item Sleep Scale (MOS) Tj ETQq1 1.0.784314rgBT /Ov	1.6	97
66	The reliability, validity and responsiveness of the International Restless Legs Syndrome Study Group rating scale and subscales in a clinical-trial setting. <i>Sleep Medicine</i> , 2006, 7, 340-349.	1.6	95
67	Increased Synaptic Dopamine in the Putamen in Restless Legs Syndrome. <i>Sleep</i> , 2013, 36, 51-57.	1.1	93
68	Restless legs syndrome augmentation associated with tramadol. <i>Sleep Medicine</i> , 2006, 7, 592-593.	1.6	92
69	A randomized, double-blind, 6-week, dose-ranging study of pregabalin in patients with restless legs syndrome. <i>Sleep Medicine</i> , 2010, 11, 512-519.	1.6	91
70	Pregnancy accounts for most of the gender difference in prevalence of familial RLS. <i>Sleep Medicine</i> , 2010, 11, 310-313.	1.6	90
71	Iron and restless legs syndrome: treatment, genetics and pathophysiology. <i>Sleep Medicine</i> , 2017, 31, 61-70.	1.6	90
72	Progressive development of augmentation during long-term treatment with levodopa in restless legs syndrome: results of a prospective multi-center study. <i>Journal of Neurology</i> , 2010, 257, 230-237.	3.6	88

#	ARTICLE	IF	CITATIONS
73	The Johns Hopkins telephone diagnostic interview for the restless legs syndrome: preliminary investigation for validation in a multi-center patient and control population. <i>Sleep Medicine</i> , 2003, 4, 137-141.	1.6	86
74	Circadian changes in CSF dopaminergic measures in restless legs syndrome. <i>Sleep Medicine</i> , 2006, 7, 263-268.	1.6	85
75	MEIS1 intronic risk haplotype associated with restless legs syndrome affects its mRNA and protein expression levels. <i>Human Molecular Genetics</i> , 2009, 18, 1065-1074.	2.9	85
76	Abnormally increased CSF 3-Ortho-methyl-dopa (3-OMD) in untreated restless legs syndrome (RLS) patients indicates more severe disease and possibly abnormally increased dopamine synthesis. <i>Sleep Medicine</i> , 2009, 10, 123-128.	1.6	85
77	New Insights into the Neurobiology of Restless Legs Syndrome. <i>Neuroscientist</i> , 2019, 25, 113-125.	3.5	85
78	Modeling the causal relationships between symptoms associated with restless legs syndrome and the patient-reported impact of RLS. <i>Sleep Medicine</i> , 2004, 5, 485-488.	1.6	81
79	Augmentation as a treatment complication of restless legs syndrome: Concept and management. <i>Movement Disorders</i> , 2007, 22, S476-S484.	3.9	81
80	Correlation between rating scales and sleep laboratory measurements in restless legs syndrome. <i>Sleep Medicine</i> , 2004, 5, 561-565.	1.6	79
81	Innovative Randomized Phase I Study and Dosing Regimen Selection to Accelerate and Inform Pivotal COVID-19 Trial of Nirmatrelvir. <i>Clinical Pharmacology and Therapeutics</i> , 2022, 112, 101-111.	4.7	76
82	The dopaminergic neurons of the A11 system in RLS autopsy brains appear normal. <i>Sleep Medicine</i> , 2009, 10, 1155-1157.	1.6	75
83	Is ferroportin hepcidin signaling altered in restless legs syndrome?. <i>Journal of the Neurological Sciences</i> , 2006, 247, 173-179.	0.6	73
84	Postmortem and imaging based analyses reveal CNS decreased myelination in restless legs syndrome. <i>Sleep Medicine</i> , 2011, 12, 614-619.	1.6	72
85	Ferritin subunits in CSF are decreased in restless legs syndrome. <i>Translational Research</i> , 2006, 147, 67-73.	2.3	70
86	Update in restless legs syndrome. <i>Current Opinion in Neurology</i> , 2010, 23, 401-406.	3.6	70
87	Brain iron deficiency in idiopathic restless legs syndrome measured by quantitative magnetic susceptibility at 7 tesla. <i>Sleep Medicine</i> , 2016, 22, 75-82.	1.6	70
88	CSF dopamine, serotonin, and biopterin metabolites in patients with restless legs syndrome. <i>Movement Disorders</i> , 2001, 16, 144-149.	3.9	69
89	Thy1 expression in the brain is affected by iron and is decreased in Restless Legs Syndrome. <i>Journal of the Neurological Sciences</i> , 2004, 220, 59-66.	0.6	69
90	Mitochondrial Ferritin in the Substantia Nigra in Restless Legs Syndrome. <i>Journal of Neuropathology and Experimental Neurology</i> , 2009, 68, 1193-1199.	1.7	68

#	ARTICLE	IF	CITATIONS
91	Pregabalin Versus Pramipexole: Effects on Sleep Disturbance in Restless Legs Syndrome. <i>Sleep</i> , 2014, 37, 635-643.	1.1	68
92	The reliability, validity and responsiveness of the Restless Legs Syndrome Quality of Life questionnaire (RLSQoL) in a trial population. <i>Health and Quality of Life Outcomes</i> , 2005, 3, 79.	2.4	66
93	A further evaluation of the cognitive deficits associated with restless legs syndrome (RLS). <i>Sleep Medicine</i> , 2008, 9, 500-505.	1.6	65
94	Pivotal Role of Adenosine Neurotransmission in Restless Legs Syndrome. <i>Frontiers in Neuroscience</i> , 2017, 11, 722.	2.8	64
95	Functional connectivity alteration of the thalamus in restless legs syndrome patients during the asymptomatic period: a resting-state connectivity study using functional magnetic resonance imaging. <i>Sleep Medicine</i> , 2014, 15, 289-294.	1.6	63
96	Systematic evaluation of augmentation during treatment with ropinirole in restless legs syndrome (Willis-Ekbom Disease): Results from a prospective, multicenter study over 66 weeks. <i>Movement Disorders</i> , 2012, 27, 277-283.	3.9	61
97	Response to intravenous iron in patients with iron deficiency anemia (IDA) and restless leg syndrome (Willis-Ekbom disease). <i>Sleep Medicine</i> , 2014, 15, 1473-1476.	1.6	55
98	Lower molecular weight intravenous iron dextran for restless legs syndrome. <i>Sleep Medicine</i> , 2013, 14, 274-277.	1.6	54
99	Low brain iron effects and reversibility on striatal dopamine dynamics. <i>Experimental Neurology</i> , 2014, 261, 462-468.	4.1	52
100	Targeting hypersensitive corticostriatal terminals in restless legs syndrome. <i>Annals of Neurology</i> , 2017, 82, 951-960.	5.3	52
101	Prevalence of restless legs syndrome and associated factors in an otherwise healthy population: results from the Danish Blood Donor Study. <i>Sleep Medicine</i> , 2017, 36, 55-61.	1.6	51
102	Predictors of health-related quality of life in sufferers with restless legs syndrome: A multi-national study. <i>Sleep Medicine</i> , 2007, 8, 73-83.	1.6	50
103	Development of the Pediatric Restless Legs Syndrome Severity Scale (P-RLS-SS)®: A patient-reported outcome measure of pediatric RLS symptoms and impact. <i>Sleep Medicine</i> , 2010, 11, 897-906.	1.6	48
104	Review of Diagnostic Instruments for the Restless Legs Syndrome/Willis-Ekbom Disease (RLS/WED): Critique and Recommendations. <i>Journal of Clinical Sleep Medicine</i> , 2014, 10, 1343-1349.	2.6	47
105	The effects of dietary iron deprivation on murine circadian sleep architecture. <i>Sleep Medicine</i> , 2006, 7, 634-640.	1.6	46
106	Clinical efficacy of ferric carboxymaltose treatment in patients with restless legs syndrome. <i>Sleep Medicine</i> , 2016, 25, 16-23.	1.6	46
107	Adenosine receptors as markers of brain iron deficiency: Implications for Restless Legs Syndrome. <i>Neuropharmacology</i> , 2016, 111, 160-168.	4.1	45
108	Evaluating daytime alertness in individuals with Restless Legs Syndrome (RLS) compared to sleep restricted controls. <i>Sleep Medicine</i> , 2009, 10, 134-138.	1.6	42

#	ARTICLE	IF	CITATIONS
109	Pharmacologic inhibition of ketohexokinase prevents fructose-induced metabolic dysfunction. <i>Molecular Metabolism</i> , 2021, 48, 101196.	6.5	42
110	Assessment of restless legs syndromeâ€™Methodological approaches for use in practice and clinical trials. <i>Movement Disorders</i> , 2007, 22, S485-S494.	3.9	40
111	Consensus diagnostic criteria for a newly defined pediatric sleep disorder: restless sleep disorder (RSD). <i>Sleep Medicine</i> , 2020, 75, 335-340.	1.6	40
112	An item response analysis of the international restless legs syndrome study group rating scale for restless legs syndrome. <i>Sleep Medicine</i> , 2005, 6, 131-139.	1.6	37
113	Systems genetic analysis of the effects of iron deficiency in mouse brain. <i>Neurogenetics</i> , 2012, 13, 147-157.	1.4	36
114	Gray matter alteration in patients with restless legs syndrome: a voxel-based morphometry study. <i>Clinical Imaging</i> , 2015, 39, 20-25.	1.5	36
115	High prevalence of restless legs syndrome/Willis Ekbohm Disease (RLS/WED) among people living at high altitude in the Indian Himalaya. <i>Sleep Medicine</i> , 2017, 35, 7-11.	1.6	36
116	Segregation Analysis of Restless Legs Syndrome: Possible Evidence for a Major Gene in a Family Study Using Blinded Diagnoses. <i>Human Heredity</i> , 2006, 62, 157-164.	0.8	35
117	Altered Iron Metabolism in Lymphocytes from Subjects with Restless Legs Syndrome. <i>Sleep</i> , 2008, 31, 847-852.	1.1	35
118	Improving RLS diagnosis and severity assessment: Polysomnography, actigraphy and RLS-sleep log. <i>Sleep Medicine</i> , 2007, 8, S13-S18.	1.6	34
119	Validation of the self-administered version of the international Restless Legs Syndrome study group severity rating scale â€™The sRLS. <i>Sleep Medicine</i> , 2019, 54, 94-100.	1.6	34
120	Efficacy Without Tolerance or Rebound Insomnia for Midazolam and Temazepam After Use for One to Three Months. <i>Journal of Clinical Pharmacology</i> , 1987, 27, 768-775.	2.0	33
121	Prevalence and clinical characteristics of patients with restless legs syndrome with painful symptoms. <i>Sleep Medicine</i> , 2015, 16, 775-778.	1.6	33
122	Proteomic analysis of the cerebrospinal fluid of patients with restless legs syndrome/Willis-Ekbom disease. <i>Fluids and Barriers of the CNS</i> , 2013, 10, 20.	5.0	32
123	Review of Severity Rating Scales for Restless Legs Syndrome: Critique and Recommendations. <i>Movement Disorders Clinical Practice</i> , 2014, 1, 317-324.	1.5	32
124	Minimal clinically significant change for the International Restless Legs Syndrome Study Group rating scale in clinical trials is a score of 3. <i>Sleep Medicine</i> , 2013, 14, 1229.	1.6	30
125	Animal models of RLS phenotypes. <i>Sleep Medicine</i> , 2017, 31, 23-28.	1.6	30
126	Diurnal variation of default mode network in patients with restless legs syndrome. <i>Sleep Medicine</i> , 2018, 41, 1-8.	1.6	29



#	ARTICLE	IF	CITATIONS
127	Altered white matter integrity in primary restless legs syndrome patients: diffusion tensor imaging study. <i>Neurological Research</i> , 2014, 36, 769-774.	1.3	28
128	Up-regulation of striatal adenosine A2A receptors with iron deficiency in rats. <i>Experimental Neurology</i> , 2010, 224, 292-298.	4.1	27
129	Assessing health-related quality of life in patients with restless legs syndrome in Korea: Comparison with other chronic medical diseases. <i>Sleep Medicine</i> , 2012, 13, 1158-1163.	1.6	27
130	Default mode network disturbances in restless legs syndrome/Willis-Ekbom disease. <i>Sleep Medicine</i> , 2016, 23, 6-11.	1.6	27
131	Augmentation of restless leg syndrome (Willis-Ekbom disease) during long-term dopaminergic treatment. <i>Postgraduate Medicine</i> , 2015, 127, 716-725.	2.0	26
132	Effects of rest-duration, time-of-day and their interaction on periodic leg movements while awake in restless legs syndrome. <i>Sleep Medicine</i> , 2005, 6, 429-434.	1.6	25
133	Prevalence and clinical characteristics of restless legs syndrome in diabetic peripheral neuropathy: comparison with chronic osteoarthritis. <i>Sleep Medicine</i> , 2013, 14, 1387-1392.	1.6	25
134	Restless legs syndrome/Willis Ekbom disease: Evaluation and treatment. <i>International Review of Psychiatry</i> , 2014, 26, 248-262.	2.8	25
135	Review of Quality of Life Instruments for the Restless Legs Syndrome/Willis-Ekbom Disease (RLS/WED): Critique and Recommendations. <i>Journal of Clinical Sleep Medicine</i> , 2014, 10, 1351-1357.	2.6	25
136	RLS and blood donation. <i>Sleep Medicine</i> , 2009, 10, 844-849.	1.6	24
137	Systems genetic analysis of multivariate response to iron deficiency in mice. <i>American Journal of Physiology - Regulatory Integrative and Comparative Physiology</i> , 2012, 302, R1282-R1296.	1.8	24
138	Snap-Gauge Compared to a Full Nocturnal Penile Tumescence Study for Evaluation of Patients with Erectile Impotence. <i>Journal of Urology</i> , 1990, 143, 51-54.	0.4	23
139	Undiagnosed individuals with first-degree relatives with restless legs syndrome have increased periodic limb movements. <i>Sleep Medicine</i> , 2006, 7, 480-485.	1.6	23
140	Restless Legs Syndrome and Periodic Limb Movements during Sleep. , 2011, , 1026-1037.		23
141	Restless legs syndrome is associated with major comorbidities in a population of Danish blood donors. <i>Sleep Medicine</i> , 2018, 45, 124-131.	1.6	23
142	Consensus Guidelines on Rodent Models of Restless Legs Syndrome. <i>Movement Disorders</i> , 2021, 36, 558-569.	3.9	23
143	We need to do better: A systematic review and meta-analysis of diagnostic test accuracy of restless legs syndrome screening instruments. <i>Sleep Medicine Reviews</i> , 2021, 58, 101461.	8.5	22
144	Restless legs syndrome and periodic leg movements in sleep. <i>Handbook of Clinical Neurology</i> / Edited By P J Vinken and G W Bruyn, 2011, 99, 913-948.	1.8	21

#	ARTICLE	IF	CITATIONS
145	Relation of the International Restless Legs Syndrome Study Group rating scale with the Clinical Global Impression severity scale, the restless legs syndrome 6-item questionnaire, and the restless legs syndrome-quality of life questionnaire. <i>Sleep Medicine</i> , 2013, 14, 1375-1380.	1.6	21
146	A Quantitative Systems Pharmacology Perspective on the Importance of Parameter Identifiability. <i>Bulletin of Mathematical Biology</i> , 2022, 84, 39.	1.9	19
147	Motor Functions and Dysfunctions of Sleep. , 2009, , 397-435.		18
148	MATPLM1, A MATLAB script for scoring of periodic limb movements: preliminary validation with visual scoring. <i>Sleep Medicine</i> , 2015, 16, 1541-1549.	1.6	18
149	Investigation into the correlation between sensation and leg movement in restless legs syndrome. <i>Movement Disorders</i> , 2005, 20, 1097-1103.	3.9	17
150	Clinical efficacy of ropinirole for restless legs syndrome is not affected by age at symptom onset. <i>Sleep Medicine</i> , 2008, 9, 899-902.	1.6	16
151	Increased Use-Dependent Plasticity in Chronic Insomnia. <i>Sleep</i> , 2014, 37, 535-544.	1.1	16
152	Efficacy of ferric carboxymaltose (FCM) 500Âmg dose for the treatment of Restless Legs Syndrome. <i>Sleep Medicine</i> , 2018, 42, 7-12.	1.6	16
153	A Prototype QSP Model of the Immune Response to SARSâ€CoVâ€2 for Community Development. <i>CPT: Pharmacometrics and Systems Pharmacology</i> , 2021, 10, 18-29.	2.5	16
154	Clinical efficacy and safety of intravenous ferric carboxymaltose treatment of pediatric restless legs syndrome and periodic limb movement disorder. <i>Sleep Medicine</i> , 2021, 87, 114-118.	1.6	16
155	Moderate to severe but not mild RLS is associated with greater sleep-related sympathetic autonomic activation than healthy adults without RLS. <i>Sleep Medicine</i> , 2020, 68, 89-95.	1.6	15
156	Iron-deficiency and dopaminergic treatment effects on RLS-Like behaviors of an animal model with the brain iron deficiency pattern of the restless legs syndrome. <i>Sleep Medicine</i> , 2020, 71, 141-148.	1.6	15
157	Sleep, Anxiety, and Depression in Abstinent and Drinking Alcoholics. <i>Substance Use and Misuse</i> , 1999, 34, 347-361.	1.4	14
158	Introduction: Towards a better understanding of the science of RLS/WED. <i>Sleep Medicine</i> , 2017, 31, 1-2.	1.6	14
159	Comparison of Subjective Sleep Quality of Long-Term Residents at Low and High Altitudes: SARAHA Study. <i>Journal of Clinical Sleep Medicine</i> , 2018, 14, 15-21.	2.6	14
160	Connecting clinical aspects to corticomotor excitability in restless legs syndrome: a TMS study. <i>Sleep Medicine</i> , 2018, 49, 105-112.	1.6	14
161	Extracellular vesicles reveal abnormalities in neuronal iron metabolism in restless legs syndrome. <i>Sleep</i> , 2019, 42, .	1.1	13
162	Diagnostic Accuracy of Behavioral, Activity, Ferritin, and Clinical Indicators of Restless Legs Syndrome. <i>Sleep</i> , 2015, 38, 371-380.	1.1	12

#	ARTICLE	IF	CITATIONS
163	Effects of rotigotine on daytime symptoms in patients with primary restless legs syndrome: a randomized, placebo-controlled study. <i>Current Medical Research and Opinion</i> , 2016, 32, 77-85.	1.9	12
164	Development and validation of a Subjective Post Sleep Diary (SPSD) to assess sleep status in subjects with Restless Legs Syndrome. <i>Sleep Medicine</i> , 2011, 12, 704-710.	1.6	9
165	A comparison of MRI tissue relaxometry and ROI methods used to determine regional brain iron concentrations in restless legs syndrome. <i>Medical Devices: Evidence and Research</i> , 2015, 8, 341.	0.8	9
166	Co-registration of magnetic resonance spectroscopy and transcranial magnetic stimulation. <i>Journal of Neuroscience Methods</i> , 2015, 242, 52-57.	2.5	9
167	Depth and Distribution of Symptoms in Restless Legs Syndrome/ Willis-Ekbom Disease. <i>Journal of Clinical Sleep Medicine</i> , 2016, 12, 1669-1680.	2.6	9
168	Association Between Non-Iron-Deficient Anemia and Insomnia Symptoms in Community-Dwelling Older Adults: The Baltimore Longitudinal Study of Aging. <i>Journals of Gerontology - Series A Biological Sciences and Medical Sciences</i> , 2018, 73, 380-385.	3.6	9
169	Resting-state connectivity and the effects of treatment in restless legs syndrome. <i>Sleep Medicine</i> , 2020, 67, 33-38.	1.6	9
170	Akathisia and Restless Legs Syndrome. <i>Sleep Medicine Clinics</i> , 2021, 16, 249-267.	2.6	9
171	Socioeconomic factors influencing the rate of non-€promotion in elementary schools. <i>Peabody Journal of Education</i> , 1977, 54, 275-281.	1.3	8
172	Valid measures of periodic leg movements (PLMs) during a suggested immobilization test using the PAM-RL leg activity monitors require adjusting detection parameters for noise and signal in each recording. <i>Sleep Medicine</i> , 2014, 15, 132-137.	1.6	8
173	Inter-movement interval as a primary stable measure of periodic limb movements of sleep. <i>Sleep Medicine</i> , 2016, 17, 138-143.	1.6	8
174	Nighttime Agitation in Persons with Dementia as a Manifestation of Restless Legs Syndrome. <i>Journal of the American Medical Directors Association</i> , 2021, 22, 1410-1414.	2.5	8
175	Randomized, placebo-controlled trial of ferric carboxymaltose in restless legs syndrome patients with iron deficiency anemia. <i>Sleep Medicine</i> , 2021, 84, 179-186.	1.6	7
176	Locating and Interviewing Alcoholics 8 Years After Discharge from Hospital. <i>Substance Use and Misuse</i> , 1988, 23, 379-386.	0.6	6
177	Article reviewed: Mortality associated with sleep duration and insomnia. <i>Sleep Medicine</i> , 2002, 3, 373-375.	1.6	6
178	Evidence for communication of peripheral iron status to cerebrospinal fluid: clinical implications for therapeutic strategy. <i>Fluids and Barriers of the CNS</i> , 2020, 17, 28.	5.0	6
179	Alcoholics' Attributions Concerning Abstinence and Returning to Drinking. <i>Alcoholism Treatment Quarterly</i> , 2004, 22, 63-79.	0.8	5
180	Restless legs syndrome symptomatology, attitudes and beliefs among treated and untreated individuals. <i>Sleep Medicine</i> , 2012, 13, 1226-1231.	1.6	5

#	ARTICLE	IF	CITATIONS
181	Defining morphology of periodic leg movements in sleep: an evidence-based definition of a minimum window of sustained activity. <i>Sleep and Breathing</i> , 2016, 20, 1293-1299.	1.7	5
182	Patient characteristics predicting responses to intravenous ferric carboxymaltose treatment of restless legs syndrome. <i>Sleep Medicine</i> , 2020, 75, 81-87.	1.6	5
183	Restless Legs Syndrome and Periodic Limb Movements During Sleep. , 2017, , 923-934.e6.		5
184	Does a modest loss of sleep affect neurocognitive functioning of children?. <i>Sleep Medicine</i> , 2003, 4, 353-355.	1.6	4
185	Alcoholics' Evaluations of Alcoholism Treatment. <i>Alcoholism Treatment Quarterly</i> , 2003, 21, 1-18.	0.8	4
186	When, if ever, can we use REM-onset naps on the MSLT for the diagnosis of narcolepsy?. <i>Sleep Medicine</i> , 2006, 7, 657-659.	1.6	4
187	Restless Legs Syndrome (Willis-Ekbom Disease) and Periodic Limb Movements. , 2012, , .		4
188	Assessment of change in restless legs syndrome symptoms during the acute drug-withdrawal period. <i>Sleep Medicine</i> , 2018, 52, 80-87.	1.6	4
189	A novel sleep stage scoring system: Combining expert-based features with the generalized linear model. <i>Journal of Sleep Research</i> , 2020, 29, e12991.	3.2	4
190	Developing a behavioral model of Restless Legs Syndrome utilizing mice with natural variances in ventral midbrain iron. <i>Sleep Medicine</i> , 2020, 71, 135-140.	1.6	4
191	Pilot study: can machine learning analyses of movement discriminate between leg movements in sleep (LMS) with vs. without cortical arousals?. <i>Sleep and Breathing</i> , 2021, 25, 373-379.	1.7	4
192	Developing a biomarker for restless leg syndrome using genome wide DNA methylation data. <i>Sleep Medicine</i> , 2021, 78, 120-127.	1.6	4
193	Diagnosis of Restless Legs Syndrome. , 2009, , 99-110.		4
194	Intervening Leg Movements Disrupt PLMS Sequences. <i>Sleep</i> , 2017, 40, .	1.1	3
195	Take afternoon naps to improve perceptual learning. <i>Sleep Medicine</i> , 2003, 4, 589-590.	1.6	2
196	Development and Validation of RLS Diagnostic Questionnaire for Indian Population. <i>Sleep and Vigilance</i> , 2019, 3, 39-48.	0.8	2
197	The Safety and Efficacy of Pregabalin Add-on Therapy in Restless Legs Syndrome Patients. <i>Frontiers in Neurology</i> , 2021, 12, 786408.	2.4	2
198	Restless legs syndrome (RLS) and periodic leg movements (PLM). , 2001, , 213-228.		1

#	ARTICLE	IF	CITATIONS
199	Response to the letter "Characterization of the painful restless legs syndrome" Sleep Medicine, 2015, 16, 1448.	1.6	1
200	0656 Validation of the Self-administered Version of the International Restless Legs Syndrome Study Group Severity Rating Scale - the sRRLS. Sleep, 2019, 42, A261-A262.	1.1	1
201	Reply to: Safety of dopamine agonists for treating restless legs syndrome. Movement Disorders, 2019, 34, 150-151.	3.9	1
202	Insight into the pathophysiology of restless legs syndrome. Journal of Neuroscience Research, 2000, 62, 623-628.	2.9	1
203	Motor Control and Dyscontrol in Sleep. , 2017, , 713-757.		1
204	Role of Striatal A2A Receptor Subpopulations in Neurological Disorders. , 2013, , 179-197.		1
205	Should we aggressively evaluate and treat sleepiness in the elderly?. Sleep Medicine, 2003, 4, 477-478.	1.6	0
206	The Restless Legs Syndrome. , 2008, , 445-467.		0
207	Response to "Characterization of the painful restless legs syndrome" Sleep Medicine, 2015, 16, 898.	1.6	0
208	Evaluation and Management of RLS and PLMD. , 2017, , 759-786.		0
209	Reply to: A note on rotigotine for restless legs syndrome after renal transplantation. Movement Disorders, 2019, 34, 152-153.	3.9	0
210	Altered expression of iron management proteins in the brain microvasculature of Restless Legs Syndrome. FASEB Journal, 2008, 22, 1191.5.	0.5	0
211	Funciones y disfunciones motoras del sueo. , 2011, , 397-435.		0
212	History of Restless Legs Syndrome, Recently Named Willis "Ekbom Disease. , 2015, , 249-254.		0
213	Association Between Anemia Subtypes and Insomnia Symptoms in Community-Dwelling Older Adults. FASEB Journal, 2015, 29, 392.7.	0.5	0